vascular bfgf recombinant murine fgf-basic Search Results


recombinant mouse fgf basic/fgf2/bfgf protein  (Bio-Techne corporation)
95
Bio-Techne corporation recombinant mouse fgf basic/fgf2/bfgf protein
Recombinant Mouse Fgf Basic/Fgf2/Bfgf Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+bfgf+recombinant+murine+fgf-basic/Recombinant+Mouse+FGF+basic%2FFGF2%2FbFGF+Protein/bio-techne+corporation___3139-fb
Average 95 stars, based on 1 article reviews
recombinant mouse fgf basic/fgf2/bfgf protein - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
recombinant murine fgf2 3139 fb  (R&D Systems)
95
R&D Systems recombinant murine fgf2 3139 fb
FGFR4 inhibition abrogates cardiac myocyte hypertrophy induced by serum from fed pythons. Neonatal rat ventricular myocytes (NRVMs) were treated with media containing either vehicle, <t>FGF2</t> (25 ng/mL), FGF23 (25 ng/mL), or serum from fasted or fed snakes (diluted to 2% of the total media volume), without or in combination with a small molecule inhibitor of FGFR4 (iFGFR4; BLU9931, 10 ng/mL), for 48 h. Compared to vehicle-treated NRVMs (Ctrl) or to NRVMs treated with serum from fasted pythons, serum collected from pythons twelve hours post-feeding (Python 12HPF; #### p < 0.0001) and three days post-feeding (Python 3DPF; #### p < 0.0001) induced a significant increase in myocyte area. When co-treated with iFGFR4 (textured bars), both Python 12HPF (**** p < 0.0001) and Python 3DPF (*** p = 0.0003) did not induce a significant increase in NRVM area when compared to the same treatment without iFGFR4. Python 12HPF ( $$$ p = 0.0003)- and Python 3DPF ( $$ p = 0.0016)-treated NRVMs had significantly increased myocyte area when compared to Python Fasted serum treatments. Treatment with recombinant FGF23 significantly increased myocyte area compared to Ctrl ( #### p < 0.0001), fasted python serum treatments ( $$$$ p < 0.0001), and FGF23 + iFGFR4 treatment (**** p < 0.0001) NRVMs. Treatment with recombinant FGF2 protein served as a positive control for hypertrophy ( ## p = 0.003). Treatment with serum from fasted and two-days-post-feeding water snakes (Water Snake Fasted, Water Snake 2DPF) served as negative controls Each individual color corresponds with the treatment indicated below the bars. # = versus Ctrl; * = versus same treatment + iFGFR4; $ = versus Python Fasted; 150 cells per condition; n = 3–4 independent isolations of NRVMs. All values are shown as mean ± SD.
Recombinant Murine Fgf2 3139 Fb, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+bfgf+recombinant+murine+fgf-basic/Recombinant+Mouse+FGF+basic%2FFGF2%2FbFGF+Protein/pmc11508992-57-2-11
Average 95 stars, based on 1 article reviews
recombinant murine fgf2 3139 fb - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
recombinant murine basic fgf  (R&D Systems)
95
R&D Systems recombinant murine basic fgf
FGFR4 inhibition abrogates cardiac myocyte hypertrophy induced by serum from fed pythons. Neonatal rat ventricular myocytes (NRVMs) were treated with media containing either vehicle, <t>FGF2</t> (25 ng/mL), FGF23 (25 ng/mL), or serum from fasted or fed snakes (diluted to 2% of the total media volume), without or in combination with a small molecule inhibitor of FGFR4 (iFGFR4; BLU9931, 10 ng/mL), for 48 h. Compared to vehicle-treated NRVMs (Ctrl) or to NRVMs treated with serum from fasted pythons, serum collected from pythons twelve hours post-feeding (Python 12HPF; #### p < 0.0001) and three days post-feeding (Python 3DPF; #### p < 0.0001) induced a significant increase in myocyte area. When co-treated with iFGFR4 (textured bars), both Python 12HPF (**** p < 0.0001) and Python 3DPF (*** p = 0.0003) did not induce a significant increase in NRVM area when compared to the same treatment without iFGFR4. Python 12HPF ( $$$ p = 0.0003)- and Python 3DPF ( $$ p = 0.0016)-treated NRVMs had significantly increased myocyte area when compared to Python Fasted serum treatments. Treatment with recombinant FGF23 significantly increased myocyte area compared to Ctrl ( #### p < 0.0001), fasted python serum treatments ( $$$$ p < 0.0001), and FGF23 + iFGFR4 treatment (**** p < 0.0001) NRVMs. Treatment with recombinant FGF2 protein served as a positive control for hypertrophy ( ## p = 0.003). Treatment with serum from fasted and two-days-post-feeding water snakes (Water Snake Fasted, Water Snake 2DPF) served as negative controls Each individual color corresponds with the treatment indicated below the bars. # = versus Ctrl; * = versus same treatment + iFGFR4; $ = versus Python Fasted; 150 cells per condition; n = 3–4 independent isolations of NRVMs. All values are shown as mean ± SD.
Recombinant Murine Basic Fgf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+bfgf+recombinant+murine+fgf-basic/Recombinant+Human+FGF-4+Protein/pmc04367527-71-42-48
Average 95 stars, based on 1 article reviews
recombinant murine basic fgf - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
fibroblastic growth factor fgf  (Gold Biotechnology Inc)
94
Gold Biotechnology Inc fibroblastic growth factor fgf
FGFR4 inhibition abrogates cardiac myocyte hypertrophy induced by serum from fed pythons. Neonatal rat ventricular myocytes (NRVMs) were treated with media containing either vehicle, <t>FGF2</t> (25 ng/mL), FGF23 (25 ng/mL), or serum from fasted or fed snakes (diluted to 2% of the total media volume), without or in combination with a small molecule inhibitor of FGFR4 (iFGFR4; BLU9931, 10 ng/mL), for 48 h. Compared to vehicle-treated NRVMs (Ctrl) or to NRVMs treated with serum from fasted pythons, serum collected from pythons twelve hours post-feeding (Python 12HPF; #### p < 0.0001) and three days post-feeding (Python 3DPF; #### p < 0.0001) induced a significant increase in myocyte area. When co-treated with iFGFR4 (textured bars), both Python 12HPF (**** p < 0.0001) and Python 3DPF (*** p = 0.0003) did not induce a significant increase in NRVM area when compared to the same treatment without iFGFR4. Python 12HPF ( $$$ p = 0.0003)- and Python 3DPF ( $$ p = 0.0016)-treated NRVMs had significantly increased myocyte area when compared to Python Fasted serum treatments. Treatment with recombinant FGF23 significantly increased myocyte area compared to Ctrl ( #### p < 0.0001), fasted python serum treatments ( $$$$ p < 0.0001), and FGF23 + iFGFR4 treatment (**** p < 0.0001) NRVMs. Treatment with recombinant FGF2 protein served as a positive control for hypertrophy ( ## p = 0.003). Treatment with serum from fasted and two-days-post-feeding water snakes (Water Snake Fasted, Water Snake 2DPF) served as negative controls Each individual color corresponds with the treatment indicated below the bars. # = versus Ctrl; * = versus same treatment + iFGFR4; $ = versus Python Fasted; 150 cells per condition; n = 3–4 independent isolations of NRVMs. All values are shown as mean ± SD.
Fibroblastic Growth Factor Fgf, supplied by Gold Biotechnology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+bfgf+recombinant+murine+fgf-basic/Basic+FGF+(FGF2)%2C+Murine/bio_rxiv__2021__06__09__447689-59-19-23
Average 94 stars, based on 1 article reviews
fibroblastic growth factor fgf - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
sag (smoothened agonist  (Merck KGaA)
90
Merck KGaA sag (smoothened agonist
FGFR4 inhibition abrogates cardiac myocyte hypertrophy induced by serum from fed pythons. Neonatal rat ventricular myocytes (NRVMs) were treated with media containing either vehicle, <t>FGF2</t> (25 ng/mL), FGF23 (25 ng/mL), or serum from fasted or fed snakes (diluted to 2% of the total media volume), without or in combination with a small molecule inhibitor of FGFR4 (iFGFR4; BLU9931, 10 ng/mL), for 48 h. Compared to vehicle-treated NRVMs (Ctrl) or to NRVMs treated with serum from fasted pythons, serum collected from pythons twelve hours post-feeding (Python 12HPF; #### p < 0.0001) and three days post-feeding (Python 3DPF; #### p < 0.0001) induced a significant increase in myocyte area. When co-treated with iFGFR4 (textured bars), both Python 12HPF (**** p < 0.0001) and Python 3DPF (*** p = 0.0003) did not induce a significant increase in NRVM area when compared to the same treatment without iFGFR4. Python 12HPF ( $$$ p = 0.0003)- and Python 3DPF ( $$ p = 0.0016)-treated NRVMs had significantly increased myocyte area when compared to Python Fasted serum treatments. Treatment with recombinant FGF23 significantly increased myocyte area compared to Ctrl ( #### p < 0.0001), fasted python serum treatments ( $$$$ p < 0.0001), and FGF23 + iFGFR4 treatment (**** p < 0.0001) NRVMs. Treatment with recombinant FGF2 protein served as a positive control for hypertrophy ( ## p = 0.003). Treatment with serum from fasted and two-days-post-feeding water snakes (Water Snake Fasted, Water Snake 2DPF) served as negative controls Each individual color corresponds with the treatment indicated below the bars. # = versus Ctrl; * = versus same treatment + iFGFR4; $ = versus Python Fasted; 150 cells per condition; n = 3–4 independent isolations of NRVMs. All values are shown as mean ± SD.
Sag (Smoothened Agonist, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+bfgf+recombinant+murine+fgf-basic/smoothened+agonist+sag/bio_rxiv__2020__06__27__175646-155-0-3
Average 90 stars, based on 1 article reviews
sag (smoothened agonist - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
recombinant mouse scf protein  (Bio-Techne corporation)
95
Bio-Techne corporation recombinant mouse scf protein
FGFR4 inhibition abrogates cardiac myocyte hypertrophy induced by serum from fed pythons. Neonatal rat ventricular myocytes (NRVMs) were treated with media containing either vehicle, <t>FGF2</t> (25 ng/mL), FGF23 (25 ng/mL), or serum from fasted or fed snakes (diluted to 2% of the total media volume), without or in combination with a small molecule inhibitor of FGFR4 (iFGFR4; BLU9931, 10 ng/mL), for 48 h. Compared to vehicle-treated NRVMs (Ctrl) or to NRVMs treated with serum from fasted pythons, serum collected from pythons twelve hours post-feeding (Python 12HPF; #### p < 0.0001) and three days post-feeding (Python 3DPF; #### p < 0.0001) induced a significant increase in myocyte area. When co-treated with iFGFR4 (textured bars), both Python 12HPF (**** p < 0.0001) and Python 3DPF (*** p = 0.0003) did not induce a significant increase in NRVM area when compared to the same treatment without iFGFR4. Python 12HPF ( $$$ p = 0.0003)- and Python 3DPF ( $$ p = 0.0016)-treated NRVMs had significantly increased myocyte area when compared to Python Fasted serum treatments. Treatment with recombinant FGF23 significantly increased myocyte area compared to Ctrl ( #### p < 0.0001), fasted python serum treatments ( $$$$ p < 0.0001), and FGF23 + iFGFR4 treatment (**** p < 0.0001) NRVMs. Treatment with recombinant FGF2 protein served as a positive control for hypertrophy ( ## p = 0.003). Treatment with serum from fasted and two-days-post-feeding water snakes (Water Snake Fasted, Water Snake 2DPF) served as negative controls Each individual color corresponds with the treatment indicated below the bars. # = versus Ctrl; * = versus same treatment + iFGFR4; $ = versus Python Fasted; 150 cells per condition; n = 3–4 independent isolations of NRVMs. All values are shown as mean ± SD.
Recombinant Mouse Scf Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+bfgf+recombinant+murine+fgf-basic/Recombinant+Mouse+SCF+Protein/custom%40455-mc%4039607037
Average 95 stars, based on 1 article reviews
recombinant mouse scf protein - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
repsox  (Enamine Ltd)
99
Enamine Ltd repsox
FGFR4 inhibition abrogates cardiac myocyte hypertrophy induced by serum from fed pythons. Neonatal rat ventricular myocytes (NRVMs) were treated with media containing either vehicle, <t>FGF2</t> (25 ng/mL), FGF23 (25 ng/mL), or serum from fasted or fed snakes (diluted to 2% of the total media volume), without or in combination with a small molecule inhibitor of FGFR4 (iFGFR4; BLU9931, 10 ng/mL), for 48 h. Compared to vehicle-treated NRVMs (Ctrl) or to NRVMs treated with serum from fasted pythons, serum collected from pythons twelve hours post-feeding (Python 12HPF; #### p < 0.0001) and three days post-feeding (Python 3DPF; #### p < 0.0001) induced a significant increase in myocyte area. When co-treated with iFGFR4 (textured bars), both Python 12HPF (**** p < 0.0001) and Python 3DPF (*** p = 0.0003) did not induce a significant increase in NRVM area when compared to the same treatment without iFGFR4. Python 12HPF ( $$$ p = 0.0003)- and Python 3DPF ( $$ p = 0.0016)-treated NRVMs had significantly increased myocyte area when compared to Python Fasted serum treatments. Treatment with recombinant FGF23 significantly increased myocyte area compared to Ctrl ( #### p < 0.0001), fasted python serum treatments ( $$$$ p < 0.0001), and FGF23 + iFGFR4 treatment (**** p < 0.0001) NRVMs. Treatment with recombinant FGF2 protein served as a positive control for hypertrophy ( ## p = 0.003). Treatment with serum from fasted and two-days-post-feeding water snakes (Water Snake Fasted, Water Snake 2DPF) served as negative controls Each individual color corresponds with the treatment indicated below the bars. # = versus Ctrl; * = versus same treatment + iFGFR4; $ = versus Python Fasted; 150 cells per condition; n = 3–4 independent isolations of NRVMs. All values are shown as mean ± SD.
Repsox, supplied by Enamine Ltd, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+bfgf+recombinant+murine+fgf-basic/RepSox/custom%40en300-23311057%4030067988
Average 99 stars, based on 1 article reviews
repsox - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
recombinant human fgf basic/fgf2/bfgf (146 aa) protein  (Bio-Techne corporation)
98
Bio-Techne corporation recombinant human fgf basic/fgf2/bfgf (146 aa) protein
FGFR4 inhibition abrogates cardiac myocyte hypertrophy induced by serum from fed pythons. Neonatal rat ventricular myocytes (NRVMs) were treated with media containing either vehicle, <t>FGF2</t> (25 ng/mL), FGF23 (25 ng/mL), or serum from fasted or fed snakes (diluted to 2% of the total media volume), without or in combination with a small molecule inhibitor of FGFR4 (iFGFR4; BLU9931, 10 ng/mL), for 48 h. Compared to vehicle-treated NRVMs (Ctrl) or to NRVMs treated with serum from fasted pythons, serum collected from pythons twelve hours post-feeding (Python 12HPF; #### p < 0.0001) and three days post-feeding (Python 3DPF; #### p < 0.0001) induced a significant increase in myocyte area. When co-treated with iFGFR4 (textured bars), both Python 12HPF (**** p < 0.0001) and Python 3DPF (*** p = 0.0003) did not induce a significant increase in NRVM area when compared to the same treatment without iFGFR4. Python 12HPF ( $$$ p = 0.0003)- and Python 3DPF ( $$ p = 0.0016)-treated NRVMs had significantly increased myocyte area when compared to Python Fasted serum treatments. Treatment with recombinant FGF23 significantly increased myocyte area compared to Ctrl ( #### p < 0.0001), fasted python serum treatments ( $$$$ p < 0.0001), and FGF23 + iFGFR4 treatment (**** p < 0.0001) NRVMs. Treatment with recombinant FGF2 protein served as a positive control for hypertrophy ( ## p = 0.003). Treatment with serum from fasted and two-days-post-feeding water snakes (Water Snake Fasted, Water Snake 2DPF) served as negative controls Each individual color corresponds with the treatment indicated below the bars. # = versus Ctrl; * = versus same treatment + iFGFR4; $ = versus Python Fasted; 150 cells per condition; n = 3–4 independent isolations of NRVMs. All values are shown as mean ± SD.
Recombinant Human Fgf Basic/Fgf2/Bfgf (146 Aa) Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+bfgf+recombinant+murine+fgf-basic/Recombinant+Human+FGF+basic%2FFGF2%2FbFGF+(146+aa)+Protein/custom%40233-fb%4032413329
Average 98 stars, based on 1 article reviews
recombinant human fgf basic/fgf2/bfgf (146 aa) protein - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
mouse/rat wnt-5a antibody  (Bio-Techne corporation)
94
Bio-Techne corporation mouse/rat wnt-5a antibody
FGFR4 inhibition abrogates cardiac myocyte hypertrophy induced by serum from fed pythons. Neonatal rat ventricular myocytes (NRVMs) were treated with media containing either vehicle, <t>FGF2</t> (25 ng/mL), FGF23 (25 ng/mL), or serum from fasted or fed snakes (diluted to 2% of the total media volume), without or in combination with a small molecule inhibitor of FGFR4 (iFGFR4; BLU9931, 10 ng/mL), for 48 h. Compared to vehicle-treated NRVMs (Ctrl) or to NRVMs treated with serum from fasted pythons, serum collected from pythons twelve hours post-feeding (Python 12HPF; #### p < 0.0001) and three days post-feeding (Python 3DPF; #### p < 0.0001) induced a significant increase in myocyte area. When co-treated with iFGFR4 (textured bars), both Python 12HPF (**** p < 0.0001) and Python 3DPF (*** p = 0.0003) did not induce a significant increase in NRVM area when compared to the same treatment without iFGFR4. Python 12HPF ( $$$ p = 0.0003)- and Python 3DPF ( $$ p = 0.0016)-treated NRVMs had significantly increased myocyte area when compared to Python Fasted serum treatments. Treatment with recombinant FGF23 significantly increased myocyte area compared to Ctrl ( #### p < 0.0001), fasted python serum treatments ( $$$$ p < 0.0001), and FGF23 + iFGFR4 treatment (**** p < 0.0001) NRVMs. Treatment with recombinant FGF2 protein served as a positive control for hypertrophy ( ## p = 0.003). Treatment with serum from fasted and two-days-post-feeding water snakes (Water Snake Fasted, Water Snake 2DPF) served as negative controls Each individual color corresponds with the treatment indicated below the bars. # = versus Ctrl; * = versus same treatment + iFGFR4; $ = versus Python Fasted; 150 cells per condition; n = 3–4 independent isolations of NRVMs. All values are shown as mean ± SD.
Mouse/Rat Wnt 5a Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+bfgf+recombinant+murine+fgf-basic/Mouse%2FRat+Wnt-5a+Antibody/bio-techne+corporation___af645
Average 94 stars, based on 1 article reviews
mouse/rat wnt-5a antibody - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
recombinant human igf-i/igf-1 protein, cf  (Bio-Techne corporation)
96
Bio-Techne corporation recombinant human igf-i/igf-1 protein, cf
FGFR4 inhibition abrogates cardiac myocyte hypertrophy induced by serum from fed pythons. Neonatal rat ventricular myocytes (NRVMs) were treated with media containing either vehicle, <t>FGF2</t> (25 ng/mL), FGF23 (25 ng/mL), or serum from fasted or fed snakes (diluted to 2% of the total media volume), without or in combination with a small molecule inhibitor of FGFR4 (iFGFR4; BLU9931, 10 ng/mL), for 48 h. Compared to vehicle-treated NRVMs (Ctrl) or to NRVMs treated with serum from fasted pythons, serum collected from pythons twelve hours post-feeding (Python 12HPF; #### p < 0.0001) and three days post-feeding (Python 3DPF; #### p < 0.0001) induced a significant increase in myocyte area. When co-treated with iFGFR4 (textured bars), both Python 12HPF (**** p < 0.0001) and Python 3DPF (*** p = 0.0003) did not induce a significant increase in NRVM area when compared to the same treatment without iFGFR4. Python 12HPF ( $$$ p = 0.0003)- and Python 3DPF ( $$ p = 0.0016)-treated NRVMs had significantly increased myocyte area when compared to Python Fasted serum treatments. Treatment with recombinant FGF23 significantly increased myocyte area compared to Ctrl ( #### p < 0.0001), fasted python serum treatments ( $$$$ p < 0.0001), and FGF23 + iFGFR4 treatment (**** p < 0.0001) NRVMs. Treatment with recombinant FGF2 protein served as a positive control for hypertrophy ( ## p = 0.003). Treatment with serum from fasted and two-days-post-feeding water snakes (Water Snake Fasted, Water Snake 2DPF) served as negative controls Each individual color corresponds with the treatment indicated below the bars. # = versus Ctrl; * = versus same treatment + iFGFR4; $ = versus Python Fasted; 150 cells per condition; n = 3–4 independent isolations of NRVMs. All values are shown as mean ± SD.
Recombinant Human Igf I/Igf 1 Protein, Cf, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+bfgf+recombinant+murine+fgf-basic/Recombinant+Human+IGF-I%2FIGF-1+Protein%2C+CF/custom%40291-g1%4032413329
Average 96 stars, based on 1 article reviews
recombinant human igf-i/igf-1 protein, cf - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
sch772984  (Selleck Chemicals)
96
Selleck Chemicals sch772984
FGFR4 inhibition abrogates cardiac myocyte hypertrophy induced by serum from fed pythons. Neonatal rat ventricular myocytes (NRVMs) were treated with media containing either vehicle, <t>FGF2</t> (25 ng/mL), FGF23 (25 ng/mL), or serum from fasted or fed snakes (diluted to 2% of the total media volume), without or in combination with a small molecule inhibitor of FGFR4 (iFGFR4; BLU9931, 10 ng/mL), for 48 h. Compared to vehicle-treated NRVMs (Ctrl) or to NRVMs treated with serum from fasted pythons, serum collected from pythons twelve hours post-feeding (Python 12HPF; #### p < 0.0001) and three days post-feeding (Python 3DPF; #### p < 0.0001) induced a significant increase in myocyte area. When co-treated with iFGFR4 (textured bars), both Python 12HPF (**** p < 0.0001) and Python 3DPF (*** p = 0.0003) did not induce a significant increase in NRVM area when compared to the same treatment without iFGFR4. Python 12HPF ( $$$ p = 0.0003)- and Python 3DPF ( $$ p = 0.0016)-treated NRVMs had significantly increased myocyte area when compared to Python Fasted serum treatments. Treatment with recombinant FGF23 significantly increased myocyte area compared to Ctrl ( #### p < 0.0001), fasted python serum treatments ( $$$$ p < 0.0001), and FGF23 + iFGFR4 treatment (**** p < 0.0001) NRVMs. Treatment with recombinant FGF2 protein served as a positive control for hypertrophy ( ## p = 0.003). Treatment with serum from fasted and two-days-post-feeding water snakes (Water Snake Fasted, Water Snake 2DPF) served as negative controls Each individual color corresponds with the treatment indicated below the bars. # = versus Ctrl; * = versus same treatment + iFGFR4; $ = versus Python Fasted; 150 cells per condition; n = 3–4 independent isolations of NRVMs. All values are shown as mean ± SD.
Sch772984, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vascular+bfgf+recombinant+murine+fgf-basic/SCH772984/bio_rxiv__2020__06__27__175646-155-21-22
Average 96 stars, based on 1 article reviews
sch772984 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

Image Search Results


FGFR4 inhibition abrogates cardiac myocyte hypertrophy induced by serum from fed pythons. Neonatal rat ventricular myocytes (NRVMs) were treated with media containing either vehicle, FGF2 (25 ng/mL), FGF23 (25 ng/mL), or serum from fasted or fed snakes (diluted to 2% of the total media volume), without or in combination with a small molecule inhibitor of FGFR4 (iFGFR4; BLU9931, 10 ng/mL), for 48 h. Compared to vehicle-treated NRVMs (Ctrl) or to NRVMs treated with serum from fasted pythons, serum collected from pythons twelve hours post-feeding (Python 12HPF; #### p < 0.0001) and three days post-feeding (Python 3DPF; #### p < 0.0001) induced a significant increase in myocyte area. When co-treated with iFGFR4 (textured bars), both Python 12HPF (**** p < 0.0001) and Python 3DPF (*** p = 0.0003) did not induce a significant increase in NRVM area when compared to the same treatment without iFGFR4. Python 12HPF ( $$$ p = 0.0003)- and Python 3DPF ( $$ p = 0.0016)-treated NRVMs had significantly increased myocyte area when compared to Python Fasted serum treatments. Treatment with recombinant FGF23 significantly increased myocyte area compared to Ctrl ( #### p < 0.0001), fasted python serum treatments ( $$$$ p < 0.0001), and FGF23 + iFGFR4 treatment (**** p < 0.0001) NRVMs. Treatment with recombinant FGF2 protein served as a positive control for hypertrophy ( ## p = 0.003). Treatment with serum from fasted and two-days-post-feeding water snakes (Water Snake Fasted, Water Snake 2DPF) served as negative controls Each individual color corresponds with the treatment indicated below the bars. # = versus Ctrl; * = versus same treatment + iFGFR4; $ = versus Python Fasted; 150 cells per condition; n = 3–4 independent isolations of NRVMs. All values are shown as mean ± SD.

Journal: Journal of Cardiovascular Development and Disease

Article Title: FGFR4 Is Required for Concentric Growth of Cardiac Myocytes during Physiologic Cardiac Hypertrophy

doi: 10.3390/jcdd11100320

Figure Lengend Snippet: FGFR4 inhibition abrogates cardiac myocyte hypertrophy induced by serum from fed pythons. Neonatal rat ventricular myocytes (NRVMs) were treated with media containing either vehicle, FGF2 (25 ng/mL), FGF23 (25 ng/mL), or serum from fasted or fed snakes (diluted to 2% of the total media volume), without or in combination with a small molecule inhibitor of FGFR4 (iFGFR4; BLU9931, 10 ng/mL), for 48 h. Compared to vehicle-treated NRVMs (Ctrl) or to NRVMs treated with serum from fasted pythons, serum collected from pythons twelve hours post-feeding (Python 12HPF; #### p < 0.0001) and three days post-feeding (Python 3DPF; #### p < 0.0001) induced a significant increase in myocyte area. When co-treated with iFGFR4 (textured bars), both Python 12HPF (**** p < 0.0001) and Python 3DPF (*** p = 0.0003) did not induce a significant increase in NRVM area when compared to the same treatment without iFGFR4. Python 12HPF ( $$$ p = 0.0003)- and Python 3DPF ( $$ p = 0.0016)-treated NRVMs had significantly increased myocyte area when compared to Python Fasted serum treatments. Treatment with recombinant FGF23 significantly increased myocyte area compared to Ctrl ( #### p < 0.0001), fasted python serum treatments ( $$$$ p < 0.0001), and FGF23 + iFGFR4 treatment (**** p < 0.0001) NRVMs. Treatment with recombinant FGF2 protein served as a positive control for hypertrophy ( ## p = 0.003). Treatment with serum from fasted and two-days-post-feeding water snakes (Water Snake Fasted, Water Snake 2DPF) served as negative controls Each individual color corresponds with the treatment indicated below the bars. # = versus Ctrl; * = versus same treatment + iFGFR4; $ = versus Python Fasted; 150 cells per condition; n = 3–4 independent isolations of NRVMs. All values are shown as mean ± SD.

Article Snippet: We used recombinant murine FGF2 (3139-FB) and FGF23 (2629-FG/CF) proteins from R&D Systems.

Techniques: Inhibition, Recombinant, Positive Control